Navigation Links
Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
Date:5/13/2010

SAN DIEGO, May 13 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced a new method for detecting antibody levels in individual patients treated with infliximab, a biologic therapy that has been used to treat more than a million patients across a number of autoimmune diseases, including rheumatoid arthritis, Crohn's disease and ulcerative colitis.

Human anti-chimeric antibody (HACA) levels have been associated with decreased duration of response and increased side effects in infliximab-treated patients (1). Current methods for detecting HACA are limited by the presence of infliximab and therefore require a minimum of 8 weeks following therapy for accurate measurement. To overcome these limitations, Prometheus has developed a proprietary highly sensitive method to measure HACA and infliximab levels in patient serum in real time. The Company believes this method can also be applied to detect other biologic drugs and their antibodies.

"Early and accurate detection of antibody levels during the course of biologic therapy may enhance our ability to assess reasons for loss of response," said David Rubin, M.D., Associate Professor of Medicine, Co-Director, University of Chicago Inflammatory Bowel Disease Center. "In addition, we anticipate that therapeutic monitoring of biologic therapy may become routine in our approach to individualizing therapies to maximize effectiveness and minimize adverse events."

Data from a preliminary study of this novel method for early detection of HACA during infliximab treatment were recently presented by Prometheus scientists at Digestive Disease Week (DDW), the largest international gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. The presentation, entitled "Measurement of Human Anti-Chimeric Antibodies (HACA) and Infliximab Levels in Patient Serum Using a Novel Homogeneous Assay," was awarded Poster of Distinction by the DDW sponsoring societies.

About Prometheus

Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California.

(1)Afif W et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May;105(5):1133-9.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
2. Prometheus Launches ProOnc Dx Cancer Diagnostics
3. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
4. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
5. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
6. DUSA Pharmaceuticals Announces Slate of Nominees for Election to the Board of Directors
7. Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
8. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
9. Cogdell Spencer Announces Commencement of Common Stock Offering
10. Mylan Announces Upsizing and Pricing of Senior Notes
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... SPRING, Md. , Dec. 2, 2016 ... new indication for Jardiance (empagliflozin) to reduce the risk ... diabetes mellitus and cardiovascular disease. "Cardiovascular ... with type 2 diabetes mellitus," said Jean-Marc Guettier ... and Endocrinology Products in FDA,s Center for Drug Evaluation ...
(Date:12/2/2016)... , December 2, 2016 ... global cardiac pacemaker market in its upcoming report titled, "Global Market Study ... a Declining CAGR of -1.4% between 2016 and 2024". The ... Mn in 2015 and this is likely to decline ... revenue, the global cardiac pacemaker market is anticipated to ...
(Date:12/2/2016)... , December 2, 2016 According to ... "Global Market Study on Automated Endoscope Reprocessors: Single Basin Automated ... of 8.6% Between 2016 and 2024 " the global automated endoscope reprocessors ... expected to expand at a CAGR of 7.2% during an ... US$ 1,367.6 Mn by 2024. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest ... patients, standing as living proof that attitude and determination can combine into the ... that spike around the holidays. This campaign will offer patients a new-found hope, ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd ... Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to ... , The demand for supplemental training related to pain management has surged ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 ... to create versatile lower third titles with just a few clicks of the mouse," ... 2 includes 30 lower third animations. Choose from various styles with accented animations, rigid ...
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 , ... ... they are winners of $1,000 each from the National Family Partnership and the Drug ... winning families who decorated their homes and the 10 winning schools who decorated their ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... treatment has announced the opening of a new eating disorder treatment center location ... outpatient treatment for adults and adolescents, both males and females ages 10 and ...
Breaking Medicine News(10 mins):